Pattern of semaglutide prescription in a real-world Canadian patient cohort

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes Pub Date : 2025-10-01 Epub Date: 2025-06-24 DOI:10.1016/j.pcd.2025.06.006

Armin Farahvash , Michelle CM Lee , Rahul Jain , Liisa Jaakkimainen

{"title":"Pattern of semaglutide prescription in a real-world Canadian patient cohort","authors":"Armin Farahvash , Michelle CM Lee , Rahul Jain , Liisa Jaakkimainen","doi":"10.1016/j.pcd.2025.06.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>Despite the growing interest in the broad applications of semaglutide, real-world data on its use in weight-loss is limited. This study aims to explore the pattern of semaglutide prescriptions in a Canadian family medicine practice.</div></div><div><h3>Methods</h3><div>This retrospective study included patients ≥ 18 years who were enrolled in Sunnybrook Academic Family practice in Toronto, Canada and prescribed semaglutide between January 2018 and April 2024. Baseline demographics, weight measurements up to 16 months, and prescription details were collected. Descriptive statistics was used to illustrate the patterns of semaglutide prescription.</div></div><div><h3>Results</h3><div>Of 9930 enrolled patients, 368 (3.71 %) were prescribed semaglutide and 335 used it. Mean age was 57.7 ± 14.1 years and 63.3 % were female. Mean BMI was 36.6 ± 7.84 kg/m<sup>2</sup>. Semaglutide was discontinued due to side effects in 11 (3.3 %) within one month and 27 (8.1 %) at any time. There was an increasing trend in semaglutide prescriptions from 2018 to 2023. There were increasing semaglutide prescriptions for weight-loss, and prescriptions by family physicians compared to specialists. Follow up measurements showed a mean weight-loss of 7.5 % in 212 patients.</div></div><div><h3>Conclusions</h3><div>In an Ontario academic family practice, semaglutide is being more frequently prescribed in the primary care setting, particularly for weight loss.</div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 512-516"},"PeriodicalIF":2.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Primary Care Diabetes","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1751991825001159","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

Despite the growing interest in the broad applications of semaglutide, real-world data on its use in weight-loss is limited. This study aims to explore the pattern of semaglutide prescriptions in a Canadian family medicine practice.

Methods

This retrospective study included patients ≥ 18 years who were enrolled in Sunnybrook Academic Family practice in Toronto, Canada and prescribed semaglutide between January 2018 and April 2024. Baseline demographics, weight measurements up to 16 months, and prescription details were collected. Descriptive statistics was used to illustrate the patterns of semaglutide prescription.

Results

Of 9930 enrolled patients, 368 (3.71 %) were prescribed semaglutide and 335 used it. Mean age was 57.7 ± 14.1 years and 63.3 % were female. Mean BMI was 36.6 ± 7.84 kg/m². Semaglutide was discontinued due to side effects in 11 (3.3 %) within one month and 27 (8.1 %) at any time. There was an increasing trend in semaglutide prescriptions from 2018 to 2023. There were increasing semaglutide prescriptions for weight-loss, and prescriptions by family physicians compared to specialists. Follow up measurements showed a mean weight-loss of 7.5 % in 212 patients.

Conclusions

In an Ontario academic family practice, semaglutide is being more frequently prescribed in the primary care setting, particularly for weight loss.

查看原文本刊更多论文

西马鲁肽在加拿大真实患者队列中的处方模式。

目的：尽管人们对西马鲁肽的广泛应用越来越感兴趣，但其在减肥中的实际应用数据有限。本研究旨在探讨西马鲁肽处方模式在加拿大家庭医学实践。方法：本回顾性研究纳入≥ 18岁的患者，这些患者于2018年1月至2024年4月在加拿大多伦多Sunnybrook学术家庭诊所登记，并服用了西马鲁肽。收集了基线人口统计数据、16个月前的体重测量数据和处方细节。描述性统计用于说明西马鲁肽处方的模式。结果：在9930例入组患者中，368例（3.71 %）处方了西马鲁肽，335例使用了西马鲁肽。平均年龄57.7 ± 14.1岁，女性63.3% %。平均BMI为36.6 ± 7.84 kg/m2。11例（3.3 %）患者在1个月内因副作用停药，27例（8.1 %）患者在任何时间停药。2018 - 2023年，西马鲁肽处方呈增加趋势。与专科医生相比，家庭医生开具的用于减肥的西马鲁肽处方越来越多。随访测量显示212例患者的平均体重减轻了7.5% %。结论：在安大略省的学术家庭实践中，西马鲁肽在初级保健环境中被更频繁地开处方，特别是减肥。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Primary Care Diabetes ENDOCRINOLOGY & METABOLISM-PRIMARY HEALTH CARE

CiteScore

5.00

自引率

3.40%

发文量

134

审稿时长

47 days

期刊介绍： The journal publishes original research articles and high quality reviews in the fields of clinical care, diabetes education, nutrition, health services, psychosocial research and epidemiology and other areas as far as is relevant for diabetology in a primary-care setting. The purpose of the journal is to encourage interdisciplinary research and discussion between all those who are involved in primary diabetes care on an international level. The Journal also publishes news and articles concerning the policies and activities of Primary Care Diabetes Europe and reflects the society''s aim of improving the care for people with diabetes mellitus within the primary-care setting.